Please assess the completion status of the following clinical trial:

Trial Title: Phase I/II Study of Chemoprevention With EGFR and COX-2 Inhibitor

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must have premalignant lesions.~* Lesion sites include oral cavity, oropharynx, and larynx.~* Must have at least a \>20 pack-year history of smoking.~* Must have a Eastern Cooperative Oncology Group (ECOG)/Zubrod performance status of 0-1.~* Participants must be 18 years of age or older.~* No contraindications for laryngoscopy and biopsy.~* Adequate liver function.~* Must have hemoglobin and hematocrit levels at or above the lower limit of the normal range.~* Participants must have prothrombin time (PT)/partial thromboplastin time (PTT) levels at or above the lower limit of the normal range.~* Women of child-bearing potential must have a negative serum pregnancy test within 72 hours of receiving treatment.~* Must be able to swallow the oral dose of erlotinib and celecoxib.~* Participants must be disease free.~* Final eligibility will be determined by the health professionals conducting the trial.~Exclusion Criteria:~* Participants with acute intercurrent illness or those who had surgery within the preceding 4 weeks unless they have fully recovered.~* History of previous malignancies unless the cancer was stage I or II and rendered free of disease more than 1 year.~* Pregnant or breast feeding.~* Not practicing adequate contraception if the participants are of child bearing potential.~* Female patients who have a positive pregnancy test.~* History or recent myocardial infarction.~* Hypertension not adequately controlled by medication.~* Documented history of coagulopathy.~* Documented history of congestive heart failure (CHF) greater than New York Heart Association (NYHA) Grade II.~* Participants who were taking COX-2 inhibitors or EGFR tyrosine kinase inhibitors within 3 months of study entry.~* Documented history or interstitial lung disease.~* Known connective tissue disease.~* History of nonsteroidal antiinflammatory drug (NSAID)-induced ulcers or those who are at risk for a GI ulcer.~* Participated in a clinical trial of an investigational drug within 12 months prior to enrollment.~* Final eligibility will be determined by the health professionals conducting the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Erlotinib & Celecoxib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).